Neumora Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Neumora Therapeutics, Inc. Common Stock (NMRA) holds an ST Score of 38.2 out of 100 (C), with its strongest factor being Forecast (A) and its weakest Momentum (F). Analysts rate NMRA Buy across 9 ratings with a $4.50 average price target (+5.2% vs the current $0.73).
- Strongest
- ForecastA
- Weakest
- MomentumF
All factor grades
- ForecastA
- GrowthB
- Financial StrengthB-
- ValuationC+
- ProfitabilityF
- MomentumF
- Piotroski2/9
Contact
NMRA stock: frequently asked questions
What is NMRA's ST Score?
Neumora Therapeutics, Inc. Common Stock (NMRA) has an ST Score of 38.2 out of 100, an overall grade of C. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NMRA a buy, sell, or hold?
Wall Street's consensus rating on NMRA is Buy based on 9 analyst ratings. Our own ST Score grades it C (38.2/100). This is data, not investment advice — always do your own research.
What is NMRA's valuation grade?
Neumora Therapeutics, Inc. Common Stock (NMRA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NMRA's growth grade?
Neumora Therapeutics, Inc. Common Stock (NMRA) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NMRA's profitability grade?
Neumora Therapeutics, Inc. Common Stock (NMRA) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NMRA's financial strength grade?
Neumora Therapeutics, Inc. Common Stock (NMRA) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NMRA?
The average analyst price target for Neumora Therapeutics, Inc. Common Stock (NMRA) is $4.50 from 9 analysts, which is +5.2% versus the recent price of $0.73.
What is NMRA's Piotroski score?
Neumora Therapeutics, Inc. Common Stock (NMRA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.